Projects

Ing. Lucia Mušáková Toporová, PhD.

International

Finished
  • Investigation of selected triorganotin compounds potentially acting as nuclear retinoid X receptor ligands in breast cancer derived cell lines by in silico and in vitro approaches
    Program: Bilateral - other
    Duration: 1. 9. 2024 – 31. 8. 2025
  • Monitoring of effects of natural and synthetic ligands of nuclear retinoid receptors on key proteins involved in epithelial-mesenchymal transition in human breast cancer cells by the mass spectrometry
    Program: Inter-academic agreement
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Antitumour effect of trialkyl- and triaryltin compounds, biologically active ligands of nuclear retinoid X receptors in human breast cancer cell lines
    Program: Inter-academic agreement
    Duration: 1. 1. 2015 – 31. 12. 2017

National

Current
  • Biologically relevant mixtures of endocrine disruptors: effects on in vitro models of ovarian intrafollicular processes and ovarian cancer cell lines
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • Investigation of new molecular regulatory mechanisms of selected biologically active 4H-pyran-4-ones in relation to their prospective applicability in human oncology
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2026
Finished
  • Molecular mechanisms of trialkyl-/triaryltin isothiocyanates\' and carboxylates\' antitumour properties - novel ligands of nuclear retinoid X receptors in rat mammary gland carcinomas and human tumour cell lines
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Molecular regulatory mechanisms and therapeutic potential of retinoid X receptor activation by triorganotin compounds in relation to breast cancer treatment
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • The safety of use of analogs of the endocrine disruptor Bisphenol A: evaluation of effects on in vitro models of ovarian intrafollicular processes and and ovarian cancer cell lines
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2020
  • Novel synergistic antitumour properties ofnuclear retinoid X receptor (RXR) agonists as a consequence of the conditional RXR-RAR heterodimer formation in human breast cancer cells
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Potential risk of metal and metal oxide nanoparticles used for biomedical applications: focus on reproductive and immune systems and brain
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Novel additive antitumour effects of nuclear retinoid X receptor (RXR) ligands of natural and synthetic character in human breast and renal carcinoma cells
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2019
  • Antitumour versus disruption effects of biologically active triaryl-/trialkyl-organometal ligands of retinoid X receptors in tissue cultures of tumour cells
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
Employees